Compare NetFlix Inc (NFLX) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetFlix Inc vs ResMed Inc. — how do they compare? NetFlix Inc trades at $76.39 (market cap $319.67B), while ResMed Inc. trades at $219.5 (market cap $31.89B). The key difference: NetFlix Inc is far larger — about 10× ResMed Inc.'s market cap, and ResMed Inc. pays a 1.19% dividend while NetFlix Inc pays none. Which is the better fit depends on your goals.
| NFLX | RMD | |
|---|---|---|
Market Cap | $319.67B | $31.89B |
Sector | Consumer Cyclical | Health |
52-Week High | $124.77 | $283.28 |
52-Week Low | $67.60 | $182.82 |
Enterprise Value | $324.85B | $31.24B |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Netflix (NFLX) is trading at $76.03, down 2.84% on the day, amid a bearish technical signal and recent price weakness. The stock is near its 52-week low, with support at $76 and resistance at $78. Fundamentally, the company shows strong revenue growth, with 2025 revenue at $45.18 billion and net income of $10.98 billion, and has beaten EPS estimates for the last three quarters. Analyst sentiment remains largely positive with a consensus buy rating and price target of $88.95, though recent news highlights concerns over the stock's performance streak.
The outlook for NFLX is mixed; strong fundamentals and analyst optimism suggest potential upside, but technical bearishness and competitive pressures pose risks. Investors should weigh robust profitability and ad-tier expansion against market volatility and execution challenges in the streaming sector.
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetFlix Inc
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
